AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
16/26/16	€0.6400	0.00%
15/26/15	€0.6400	-7.38%
14/26/14	€0.6910	-4.16%
13/26/13	€0.7210	-2.70%
10/26/10	€0.7410	+0.14%

Delayed Quote Deutsche Boerse AG

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Tradegate Other stock markets 08:00:11 16/07/2026 pm IST			5-day change	1st Jan Change
0.6220 ^EUR	-2.81%		-13.51%	-53.08%

01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI

Market Cap	5.16Cr 5.9Cr 4.76Cr 4.38Cr 8.29Cr 567.99Cr 8.43Cr 57Cr 22Cr 277.62Cr 22Cr 22Cr 956.88Cr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.16Cr 5.9Cr 4.76Cr 4.38Cr 8.29Cr 567.99Cr 8.43Cr 57Cr 22Cr 277.62Cr 22Cr 22Cr 956.88Cr	EV / Sales 2026 *	43x	EV / Sales 2027 *	39.7x
Free-Float	63.24%	Yield 2026 *	-	Yield 2027 *	-

01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
29/06	AB Science completes Step 3 of a Phase 1 study
18/06	AB Science Secures US Patent for Prostate Cancer Therapy	MT
18/06	AB Science Secures New U.S. Patent for Masitinib
17/06	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
10/06	AB Science presents new data on Masitinib
18/05	AB Science S.A. announced that it has received $2.989368 million in funding	CI
13/05	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04/05	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
29/04	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
29/04	AB Science announces successful capital increase

10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
01/07	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ

AB Science Share Price Deutsche Boerse AG

Stocks

A8D

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

13/07	Bourse : Go West pour Stellantis, Apple se fâche contre OpenAI, Akzo courtisé
13/07	Wall Street ne chômera pas le 14 juillet
10/07	AB Science rationalise son portefeuille et se recentre sur deux molécules
10/07	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
08/07	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG

1 day	-2.81%
1 week	-13.51%
Current month	-28.33%
1 month	-27.60%
3 months	-47.54%
6 months	-54.42%
Current year	-53.08%

1 week	0.64	0.74
1 month	0.64	0.99
Current year	0.64	1.55
1 year	0.64	1.6
3 years	0.64	4.07
5 years	0.64	15.72
10 years	0.64	20.1

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-2.81%	-13.51%	-	-	5.9Cr
MERCK & CO., INC.	+2.62%	+1.90%	+54.62%	+20.73%	31TCr
MERCK KGAA	-2.25%	-1.58%	+24.40%	-7.66%	6.97TCr
HALOZYME THERAPEUTICS, INC.	+1.74%	-1.04%	+34.12%	+93.21%	899.32Cr
KYOWA KIRIN CO., LTD.	+0.23%	-1.07%	+6.05%	-1.03%	852.39Cr
BETTA PHARMACEUTICALS CO., LTD.	-3.81%	+8.29%	+14.34%	+32.17%	417.22Cr
SK BIOPHARMACEUTICALS CO., LTD.	+4.83%	-4.75%	-20.93%	+2.22%	411.08Cr
YUHAN CORPORATION	+4.20%	+0.58%	-38.39%	+22.65%	347.93Cr
SUPERNUS PHARMACEUTICALS, INC.	+0.18%	-1.23%	+43.65%	+63.61%	277.02Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+4.15%	+8.99%	+15.78%	-15.61%	227.73Cr
Average	+0.93%	-0.84%	+14.85%	+23.36%	4.55TCr
Weighted average by Cap.	+1.69%	-4.72%	+45.76%	+17.07%

	2026 *	2027 *
Net sales	12L 13.73L 11.07L 10.18L 19.28L 13Cr 19.61L 1.32Cr 51.85L 6.46Cr 51.54L 50.41L 22Cr	13L 14.87L 11.99L 11.02L 20.89L 14Cr 21.24L 1.43Cr 56.18L 6.99Cr 55.84L 54.62L 24Cr
Net income	-	-
Net Debt	-	-